Differential Protein-Coding Gene Expression Profile in Patients with Prostate Cancer
Background: Prostate cancer is the second most common neoplasm in men, with projections estimating over one million new cases by 2045. Differentially expressed genes can significantly enhance the diagnosis, treatment, monitoring, and prognosis of this disease. Purpose: to systematically review and a...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/12/11/2509 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850217200676241408 |
|---|---|
| author | Lorena Albarracín-Navas Maylin Almonte-Becerril Enmanuel Guerrero Josue Rivadeneira Marcelino Telechea-Fernández Elizabeth Guzmán Fanny Calderón María José Hernández-Leal Tamara Otzen Carlos Manterola Galo Duque Ángela L. Riffo-Campos |
| author_facet | Lorena Albarracín-Navas Maylin Almonte-Becerril Enmanuel Guerrero Josue Rivadeneira Marcelino Telechea-Fernández Elizabeth Guzmán Fanny Calderón María José Hernández-Leal Tamara Otzen Carlos Manterola Galo Duque Ángela L. Riffo-Campos |
| author_sort | Lorena Albarracín-Navas |
| collection | DOAJ |
| description | Background: Prostate cancer is the second most common neoplasm in men, with projections estimating over one million new cases by 2045. Differentially expressed genes can significantly enhance the diagnosis, treatment, monitoring, and prognosis of this disease. Purpose: to systematically review and analyze validated differentially expressed mRNAs in prostate cancer patients to propose a robust molecular profile for clinical diagnostics. Methods: A systematic review was conducted following PRISMA guidelines, searching literature databases for mRNAs with validated differential expression in adult prostate cancer patients. Identified mRNAs were analyzed using STRING, Cytoscape, and DrugBank to explore protein–protein interactions and potential drug targets. Results: A total of 5003 participants from Europe, Asia, America, and Oceania were included, and 144 mRNAs (<i>p</i> < 0.05) were reported across 75 primary articles, predominantly validated using RT-qPCR with tissue samples. Among these, at least 36 mRNAs were identified as targets for cancer-related drugs. Enrichment analysis revealed the top pathways were associated with cancer, including specific prostate cancer terms. Key nodes emerged as hubs in the protein–protein interaction network. Conclusion: Based on our comprehensive in silico analysis of validated differentially expressed mRNAs, we propose a molecular profile of twenty-five mRNAs with significant potential for clinical diagnosis of prostate cancer. These findings offer a valuable foundation for developing precision oncology strategies to improve patient outcomes. |
| format | Article |
| id | doaj-art-2c3b6fd398d34ac193347d3ca0dbb658 |
| institution | OA Journals |
| issn | 2227-9059 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-2c3b6fd398d34ac193347d3ca0dbb6582025-08-20T02:08:08ZengMDPI AGBiomedicines2227-90592024-11-011211250910.3390/biomedicines12112509Differential Protein-Coding Gene Expression Profile in Patients with Prostate CancerLorena Albarracín-Navas0Maylin Almonte-Becerril1Enmanuel Guerrero2Josue Rivadeneira3Marcelino Telechea-Fernández4Elizabeth Guzmán5Fanny Calderón6María José Hernández-Leal7Tamara Otzen8Carlos Manterola9Galo Duque10Ángela L. Riffo-Campos11Universidad de La Frontera, Ph.D. Program in Medical Sciences, Temuco 4811230, ChileExecutive Direction of Research and Advanced Studies, Universidad de la Salud, Mexico City 01210, MexicoUniversidad de La Frontera, Ph.D. Program in Medical Sciences, Temuco 4811230, ChileUniversidad de La Frontera, Ph.D. Program in Medical Sciences, Temuco 4811230, ChileFaculty of Chemistry, Complutense University of Madrid, 28040 Madrid, SpainComprehensive Medical Services (SERMEDIC), Cuenca 010111, EcuadorSOLCA Cancer Institute, Cuenca 010111, EcuadorUniversidad de La Frontera, Ph.D. Program in Medical Sciences, Temuco 4811230, ChileUniversidad de La Frontera, Ph.D. Program in Medical Sciences, Temuco 4811230, ChileUniversidad de La Frontera, Ph.D. Program in Medical Sciences, Temuco 4811230, ChileFaculty of Medicine, Universidad del Azuay, Cuenca 010107, EcuadorUniversidad de La Frontera, Ph.D. Program in Medical Sciences, Temuco 4811230, ChileBackground: Prostate cancer is the second most common neoplasm in men, with projections estimating over one million new cases by 2045. Differentially expressed genes can significantly enhance the diagnosis, treatment, monitoring, and prognosis of this disease. Purpose: to systematically review and analyze validated differentially expressed mRNAs in prostate cancer patients to propose a robust molecular profile for clinical diagnostics. Methods: A systematic review was conducted following PRISMA guidelines, searching literature databases for mRNAs with validated differential expression in adult prostate cancer patients. Identified mRNAs were analyzed using STRING, Cytoscape, and DrugBank to explore protein–protein interactions and potential drug targets. Results: A total of 5003 participants from Europe, Asia, America, and Oceania were included, and 144 mRNAs (<i>p</i> < 0.05) were reported across 75 primary articles, predominantly validated using RT-qPCR with tissue samples. Among these, at least 36 mRNAs were identified as targets for cancer-related drugs. Enrichment analysis revealed the top pathways were associated with cancer, including specific prostate cancer terms. Key nodes emerged as hubs in the protein–protein interaction network. Conclusion: Based on our comprehensive in silico analysis of validated differentially expressed mRNAs, we propose a molecular profile of twenty-five mRNAs with significant potential for clinical diagnosis of prostate cancer. These findings offer a valuable foundation for developing precision oncology strategies to improve patient outcomes.https://www.mdpi.com/2227-9059/12/11/2509prostate cancermolecular targetsgene expressionmRNAs |
| spellingShingle | Lorena Albarracín-Navas Maylin Almonte-Becerril Enmanuel Guerrero Josue Rivadeneira Marcelino Telechea-Fernández Elizabeth Guzmán Fanny Calderón María José Hernández-Leal Tamara Otzen Carlos Manterola Galo Duque Ángela L. Riffo-Campos Differential Protein-Coding Gene Expression Profile in Patients with Prostate Cancer Biomedicines prostate cancer molecular targets gene expression mRNAs |
| title | Differential Protein-Coding Gene Expression Profile in Patients with Prostate Cancer |
| title_full | Differential Protein-Coding Gene Expression Profile in Patients with Prostate Cancer |
| title_fullStr | Differential Protein-Coding Gene Expression Profile in Patients with Prostate Cancer |
| title_full_unstemmed | Differential Protein-Coding Gene Expression Profile in Patients with Prostate Cancer |
| title_short | Differential Protein-Coding Gene Expression Profile in Patients with Prostate Cancer |
| title_sort | differential protein coding gene expression profile in patients with prostate cancer |
| topic | prostate cancer molecular targets gene expression mRNAs |
| url | https://www.mdpi.com/2227-9059/12/11/2509 |
| work_keys_str_mv | AT lorenaalbarracinnavas differentialproteincodinggeneexpressionprofileinpatientswithprostatecancer AT maylinalmontebecerril differentialproteincodinggeneexpressionprofileinpatientswithprostatecancer AT enmanuelguerrero differentialproteincodinggeneexpressionprofileinpatientswithprostatecancer AT josuerivadeneira differentialproteincodinggeneexpressionprofileinpatientswithprostatecancer AT marcelinotelecheafernandez differentialproteincodinggeneexpressionprofileinpatientswithprostatecancer AT elizabethguzman differentialproteincodinggeneexpressionprofileinpatientswithprostatecancer AT fannycalderon differentialproteincodinggeneexpressionprofileinpatientswithprostatecancer AT mariajosehernandezleal differentialproteincodinggeneexpressionprofileinpatientswithprostatecancer AT tamaraotzen differentialproteincodinggeneexpressionprofileinpatientswithprostatecancer AT carlosmanterola differentialproteincodinggeneexpressionprofileinpatientswithprostatecancer AT galoduque differentialproteincodinggeneexpressionprofileinpatientswithprostatecancer AT angelalriffocampos differentialproteincodinggeneexpressionprofileinpatientswithprostatecancer |